Bank of America Initiates Coverage on Eurand N.V. (EURX) with a Neutral
More News related to EURX
- Eurand Announces Conference Call on Fourth Quarter and Full-Year 2009 Financial Results
- Eurand to Present at Deutsche Bank Securities Small- and Mid-Cap Conference
- Caris & Co. Initiates Coverage on Eurand N.V. (EURX) with a Buy
- Eurand N.V. (EURX) Announces Availability of ZENPEP
- Eurand (EURX) Announced Phase II/III Data for Pancreatic Enzyme Product ZENPEP
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Bank of America initiates coverage on Eurand N.V. (Nasdaq: EURX) with a Neutral rating. Price target $15.
To see more analyst ratings on EURX Click Here.
Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products.
Related Categories
New CoverageStocks Mentioned
-0.20Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
